Granite Point Capital Management’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

Granite Point Capital Management’s Portfolio EUCRW Stock Details EUCRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-133,332	Closed	-$7.08K	–	107
2022 Q4	$7.08K	Hold	133,332	–	–	﹤0.01%	88
2022 Q3	$5K	Hold	133,332	–	–	﹤0.01%	103
2022 Q2	$9K	Hold	133,332	–	–	﹤0.01%	107
2022 Q1	$25K	Hold	133,332	–	–	0.01%	122
2021 Q4	$77K	Hold	133,332	–	–	0.01%	125
2021 Q3	$107K	Hold	133,332	–	–	0.01%	130
2021 Q2	$138K	Hold	133,332	–	–	0.01%	153
2021 Q1	$167K	Buy	+133,332	New	+$216K	0.01%	175

Other funds holding EUCRW

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

HIM

HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

Granite Point Capital Management's EUCRW Position: Q1 2023 in Review

Granite Point Capital Management sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q1 2023, closing a stake of 133,332 shares — an estimated $7.08K sold.

Granite Point Capital Management first reported a position in EUCRW in Q1 2021 and held it in 8 quarters. The position peaked at $167K in Q1 2021. 22 funds tracked by Wall St. Rank hold EUCRW as of Q1 2023.

Granite Point Capital Management reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q1 2023 after selling out during the quarter.
Granite Point Capital Management sold 133,332 Eucrates Biomedical Acquisition Corp. Warrant shares in Q1 2023, an estimated $7.08K.
Granite Point Capital Management first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q1 2021 and held it in 8 quarters.
Granite Point Capital Management's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $167K in Q1 2021.
22 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q1 2023.

Based on Granite Point Capital Management's 13F filing for Q1 2023, filed 11 May 2023.